EntreMed says 2ME2 decreases inflammation in rheumatoid arthritis

By Elaine Rigoli

Tampa, Fla., March 22 - EntreMed, Inc. presented preclinical data for its rheumatoid arthritis lead compound, 2-methoxyestradiol (2ME2).

Preclinical studies demonstrate that daily oral administration of 2ME2 resulted in a dose-dependent decrease in inflammation and tissue destruction in accepted rheumatoid arthritis models, according to a company news release.

Disease progression was blocked by treatment with 2ME2 based on quantitative histological analyses of tissue from a collagen-induced arthritis model.

Two parameters for assessing inflammatory responses, infiltration of leukocytes (white blood cells) and pannus (destructive joint tissue) severity, showed a clear dose-dependent improvement with 2ME2 treatment, the release said.

In addition, cartilage lesion and bone resorption severity scores, two parameters that assess the extent of tissue destruction, also displayed a dose-dependent decline following treatment with 2ME2.

In these preclinical models, treatment with 100 mg/kg of 2ME2 was nearly 100% effective in the inhibition of inflammatory response and tissue destructive processes.

Moreover, abnormal angiogenesis associated with the progression of the rheumatoid pannus was virtually eliminated with 2ME2 treatment, the release said.

EntreMed is a Rockville, Md.-based clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.